Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Shareholders' Equity (Unaudited)

v3.20.2
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
Common Stock
Additional Paid In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2018 $ 6,863 $ 16,469,818 $ (12,035,370) $ 4,441,311
Balance, shares at Dec. 31, 2018 6,862,499      
Equity-based compensation - stock option expense 129,150 129,150
Equity-based compensation - stock issuances to consultants $ 94 154,760 154,854
Equity-based compensation - stock issuances to consultants, shares 93,750      
Warrant modification expense 441,763 441,763
Sale of Common Stock & Warrants, net of expenses $ 2,845 9,243,404 9,246,249
Sale of Common Stock & Warrants 2,845,000      
Offering Issuance Cost   (1,050,576)   (1,050,576)
Exercise of warrants $ 367 1,050,270 1,050,637
Exercise of warrants, shares 367,577      
Net loss (2,682,651) (2,682,651)
Balance at Mar. 31, 2019 $ 10,169 26,438,589 (14,718,021) 11,730,737
Balance, shares at Mar. 31, 2019 10,168,826      
Equity-based compensation - stock option expense 310,210 310,210
Equity-based compensation - stock issuances to consultants $ 69 154,181 154,250
Equity-based compensation - stock issuances to consultants, shares 68,750      
Exercise of warrants $ 4 22 26
Exercise of warrants, shares 4,873      
Net loss (2,134,407) (2,134,407)
Balance at Jun. 30, 2019 $ 10,242 26,903,002 $ (16,852,428) 10,060,816
Balance, shares at Jun. 30, 2019 10,242,449      
Equity-based compensation - stock option expense   313,619   313,619
Equity-based compensation - stock issuances to consultants $ 19 71,231   71,250
Equity-based compensation - stock issuances to consultants, shares 18,750      
Exercise of warrants $ 34 144   $ 178
Exercise of warrants, shares 33,661      
Sale of common stock, net of expenses, shares     (1,715,883) (1,715,883)
Balance at Sep. 30, 2019 $ 10,295 27,287,996 $ (18,568,311) $ 8,729,980
Balance, shares at Sep. 30, 2019 10,294,860      
Balance at Dec. 31, 2019 $ 10,368 27,757,017 (20,626,799) 7,140,586
Balance, shares at Dec. 31, 2019 10,368,352      
Equity-based compensation - stock option expense 342,007 342,007
Equity-based compensation - stock and warrant issuances to consultants and employees $ 261 345,366 345,627
Equity-based compensation - stock and warrant issuances to consultants and employees, shares 261,251      
Net loss (2,276,813) (2,276,813)
Balance at Mar. 31, 2020 $ 10,629 28,444,390 (22,903,612) 5,551,407
Balance, shares at Mar. 31, 2020 10,629,603      
Equity-based compensation - stock option expense   385,648 385,648
Equity-based compensation - stock and warrant issuances to consultants and employees 9,804 9,804
Equity-based compensation - stock and warrant issuances to consultants and employees, shares      
Sale of common stock, net of expenses $ 2,820 4,654,395 4,657,215
Sale of common stock, net of expenses, shares 2,820,000      
Net loss     (1,811,110) (1,811,110)
Balance at Jun. 30, 2020 $ 13,449 33,494,237 (24,714,722) 7,085,145
Balance, shares at Jun. 30, 2020 13,449,603      
Equity-based compensation - stock option expense   348,185   348,185
Equity-based compensation - stock and warrant issuances to consultants and employees $ 185 329,622   329,807
Equity-based compensation - stock and warrant issuances to consultants and employees, shares 185,000      
Exercise of warrants $ 227 449,781   450,008
Exercise of warrants, shares 226,354      
Sale of common stock, net of expenses $ 357 499,643   500,000
Sale of common stock, net of expenses, shares 357,143      
Net loss     (3,335,819) (3,335,819)
Balance at Sep. 30, 2020 $ 14,218 $ 35,121,468 $ (28,050,541) $ 7,085,145
Balance, shares at Sep. 30, 2020 14,218,100